HOOKIPA Pharma to Participate in the Van Lanschot Kempen Life Sciences Conference

Rhea-AI Summary

HOOKIPA Pharma Inc. (NASDAQ: HOOK), a biopharmaceutical company specializing in immunotherapies, announced its participation in investor meetings at the Van Lanschot Kempen Life Sciences Conference in Amsterdam on April 25-26, 2023. This event highlights HOOKIPA's commitment to advancing its proprietary arenavirus platform aimed at fighting serious diseases.

HOOKIPA is focused on developing therapies that enhance T cell responses to combat various cancers, including Human Papillomavirus 16-positive cancers and prostate cancers. Additionally, the company collaborates with Roche on treatments for KRAS-mutated cancers and aims to create functional cures for HBV and HIV alongside Gilead.

News Market Reaction – HOOK

-0.61%

-0.61% Session move

In the trading session that priced this news, HOOK declined 0.61%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK and VIENNA, Austria, April 19, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced today that the company will participate in investor meetings at the Van Lanschot Kempen Life Sciences Conference being held in Amsterdam, April 25 - 26, 2023.

About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, prostate cancers, and other undisclosed oncology programs. HOOKIPA is collaborating with Roche on an arenaviral immunotherapeutic for KRAS-mutated cancers. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.

Find out more about HOOKIPA online at www.hookipapharma.com.

For further information, please contact:

Media	Investors
Instinctif Partners	Matt Beck
hookipa@instinctif.com	Executive Director – Investor Relations
+44 (0)20 7457 2020	matthew.beck@hookipapharma.com

FAQ

When and where is HOOKIPA participating in investor meetings?

HOOKIPA will participate in investor meetings at the Van Lanschot Kempen Life Sciences Conference in Amsterdam on April 25-26, 2023.

What is the focus of HOOKIPA Pharma's research and development?

HOOKIPA Pharma focuses on developing novel immunotherapies using its proprietary arenavirus platform to mobilize T cells for combating serious diseases.

What types of cancers is HOOKIPA targeting with its therapies?

HOOKIPA is targeting Human Papillomavirus 16-positive cancers, prostate cancers, and other undisclosed oncology programs.

Who is collaborating with HOOKIPA on cancer treatments?

HOOKIPA is collaborating with Roche on an arenaviral immunotherapeutic for KRAS-mutated cancers.

What are HOOKIPA's goals regarding HBV and HIV?

HOOKIPA aims to develop functional cures for HBV and HIV in collaboration with Gilead.